Axcellant appointed Global CRO for Santersus’ multinational pivotal study in sepsis

  • Home
  • Newsroom
  • Axcellant appointed Global CRO for Santersus’ multinational pivotal study in sepsis
Axcellant appointed Global CRO for Santersus’ multinational pivotal study in sepsis - Axcellant

Axcellant appointed Global CRO for Santersus’ multinational pivotal study in sepsis

  1. Oct 26, 2026

Axcellant, a specialist global contract research organization (CRO), has been appointed by Switzerland-based Santersus AG to support the execution of NUC-CAP, a multinational pivotal clinical study evaluating the safety and effectiveness of NucleoCapture® in critically ill patients with sepsis and respiratory failure.

NUC-CAP is a multicentre, randomized pivotal study expected to enroll up to 350 patients across clinical sites in the United States and Europe. The study will investigate whether Santersus’ proprietary blood purification technology can selectively remove circulating neutrophil extracellular traps (NETs) and deliver clinically meaningful benefits. Key endpoints include all-cause mortality and organ support-free days through Day 28.

As the global CRO supporting NUC-CAP, Axcellant will provide integrated clinical development capabilities across key areas of study execution, including global clinical operations, study start-up, medical monitoring, pharmacovigilance, and clinical program coordination.

“We are pleased to support Santersus in the global execution of NUC-CAP”, said Wojciech Kula, CEO of Axcellant. “The study represents an important clinical undertaking in a critically ill patient population, and our team will bring integrated clinical-development capabilities to support disciplined execution across participating regions”.

According to Santersus’ development timeline, the first interim analysis, involving 100 patients, is targeted for Q4 2027, alongside an anticipated EU regulatory submission.

Axcellant’s involvement in NUC-CAP represents its expertise in supporting complex, multinational clinical programs, and its pledge to advancing innovative medical technologies using rigorous clinical research.

Resources

Axcellant to Attend EANM 2026 in Vienna

Axcellant will participate in the Annual Congress of the European Association of Nuclear Medicine (EANM 2026), taking place from 17…

Large Language Models in Nuclear Cardiology: From Experimental Tools to Clinical Infrastructure

3 Questions with: Prof. Piotr Słomka Large language models are entering nuclear cardiology at a pace that makes the usual…

From Half-Life to Clinical Impact: Mastering Time-Critical Supply Chains

How Axcellant helped a diagnostic study overcome isotope supply, manufacturing, and logistics constraints In radiopharmaceutical development, we often say that…